Systematic review and meta-analysis of vesical imaging-reporting and data system (VI-RADS) inter-observer reliability : an added value for muscle invasive bladder cancer detection by Del Giudice, F.D. et al.
This is a repository copy of Systematic review and meta-analysis of vesical imaging-
reporting and data system (VI-RADS) inter-observer reliability : an added value for muscle 
invasive bladder cancer detection.




Del Giudice, F.D., Pecoraro, M., Vargas, H.A. et al. (8 more authors) (2020) Systematic 
review and meta-analysis of vesical imaging-reporting and data system (VI-RADS) inter-
observer reliability : an added value for muscle invasive bladder cancer detection. 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
cancers
Article
Systematic Review and Meta-Analysis of Vesical
Imaging-Reporting and Data System (VI-RADS)
Inter-Observer Reliability: An Added Value for
Muscle Invasive Bladder Cancer Detection
Francesco Del Giudice 1,2,* , Martina Pecoraro 3, Hebert Alberto Vargas 4, Stefano Cipollari 3,
Ettore De Berardinis 1, Marco Bicchetti 3, Benjamin I. Chung 2, Carlo Catalano 3,
Yoshifumi Narumi 5, James W. F. Catto 6 and Valeria Panebianco 3
1 Department of Maternal-Infant and Urological Sciences, “Sapienza” University of Rome,
Policlinico Umberto I Hospital, 00161 Rome, Italy; ettore.deberardinis@uniroma1.it
2 Department of Urology, Stanford University, School of Medicine, Stanford, CA 94305, USA;
bichung@uniroma1.it
3 Department of Radiological Sciences, Oncology and Pathology, “Sapienza”/Policlinico Umberto I,
00161 Rome, Italy; martina.pecoraro@uniroma1.it (M.P.); stefano.cipollari@uniroma1.it (S.C.);
marco.bicchetti@uniroma1.it (M.B.); carlo.catalano@uniroma1.it (C.C.);
valeria.panebianco@uniroma1.it (V.P.)
4 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
vargasah@mskcc.org
5 Departments of Radiology and Health Science, Kyoto Tachibana University, Kyoto 607-8175, Japan;
naru21747@gmail.com
6 Academic Urology Unit, University of Sheffield, Sheffield S10 2TN, UK; j.catto@sheffield.ac.uk
* Correspondence: francesco.delgiudice@uniroma1.it; Tel.: +39-064-997-4201; Fax: +39-064-997-8509
Received: 5 September 2020; Accepted: 9 October 2020; Published: 15 October 2020


Simple Summary: In our systematic review and meta-analysis of eight observational studies
including a total of 1016 patients, we demonstrated excellent pooled inter-observer agreement among
Genito-Urinary radiologists when adopting the novel Vesical Imaging-Reporting and Data System
(VI-RADS) criteria in the pre-trans-urethral resection of bladder tumor (TURBT) assessment for
non-muscle (NMIBC) vs. muscle-invasive bladder cancer (MIBC) detection.
Abstract: The Vesical Imaging-Reporting and Data System (VI-RADS) has been introduced to provide
preoperative bladder cancer staging and has proved to be reliable in assessing the presence of
muscle invasion in the pre-TURBT (trans-urethral resection of bladder tumor). We aimed to assess
through a systematic review and meta-analysis the inter-reader variability of VI-RADS criteria for
discriminating non-muscle vs. muscle invasive bladder cancer (NMIBC, MIBC). PubMed, Web of
Science, Cochrane, and Embase were searched up until 30 July 2020. The Quality Appraisal of
Diagnostic Reliability (QAREL) checklist was utilized to assess the quality of included studies and a
pooled measure of inter-rater reliability (Cohen’s Kappa [κ] and/or Intraclass correlation coefficients
(ICCs)) was calculated. Further sensitivity analysis, subgroup analysis, and meta-regression were
conducted to investigate the contribution of moderators to heterogeneity. In total, eight studies
between 2018 and 2020, which evaluated a total of 1016 patients via 21 interpreting genitourinary
(GU) radiologists, met inclusion criteria and were critically examined. No study was considered
to be significantly flawed with publication bias. The pooled weighted mean κ estimate was 0.83
(95%CI: 0.78–0.88). Heterogeneity was present among the studies (Q = 185.92, d.f. = 7, p < 0.001;
I2 = 92.7%). Meta-regression analyses showed that the relative % of MIBC diagnosis and cumulative
reader’s experience to influence the estimated outcome (Coeff: 0.019, SE: 0.007; p= 0.003 and 0.036,
SE: 0.009; p = 0.001). In the present study, we confirm excellent pooled inter-reader agreement
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of VI-RADS to discriminate NMIBC from MIBC underlying the importance that standardization
and reproducibility of VI-RADS may confer to multiparametric magnetic resonance (mpMRI) for
preoperative BCa staging.
Keywords: bladder cancer; VI-RADS; multiparametric magnetic resonance imaging; muscle-invasive
bladder cancer; inter-reader agreement; bladder cancer staging
1. Introduction
The indications for multiparametric magnetic resonance imaging (mpMRI) for bladder cancer
(BCa) are recently expanding and have demonstrated reliable accuracy in staging applications [1–6].
The Vesical Imaging-Reporting and Data System (VI-RADS) has been introduced to provide preoperative
BCa staging and has been prospectively shown to be reliable in assessing the presence of muscle
invasion in the pre-TURBT (trans-urethral resection of bladder tumor) setting [7,8]. In particular,
the VI-RADS scale consists of a 5-point score for each of the sequences in the acquisition protocol
(T2-weighted, Diffusion-weighted imaging [DWI], and Dynamic contrast enhanced [DCE]) combined to
obtain an overall sum which predict the likelihood of muscle-invasive disease (muscle invasive bladder
cancer (MIBC), i.e., VI-RADS ≥ 3). After its introduction in April 2018, two separate meta-analyses have
shown excellent overall pooled diagnostic accuracy for VI-RADS score ≥ 3, with Area Under the Curve
(AUC) of 0.94 (95% confidence interval [CI], 0.91–0.95) and 0.93 (95% CI 0.91–0.95), respectively [9,10].
As described in the seminal document [7], the applicability of VI-RADS may extend beyond its intrinsic
diagnostic and staging value, leading VI-RADS to act as a predictive tool for several clinical scenarios
indicating those non-muscle invasive bladder cancer (NMIBC)’s for secondary resection (Re-TURBT) or
as a radiation-free modality to monitor radiological response of MIBC patients eligible for neoadjuvant
systemic regimens [8,11,12]. One of the most important and underappreciated aspect of VI-RADS is
to provide a systematic and standardized approach to define the risk of muscle invasion. VI-RADS
should not therefore be interpreted as a mpMRI competitor for BCa staging, but its complementary
development to fill the inter-rater variability gap among radiologists, that in the past prevented the
widespread adoption of MRI due to lack of uniform systems and expertise resulting in divergent
MRI performance, in different radiology settings. The aim of the present systematic review and
meta-analysis is therefore to cumulatively report inter-reader agreement estimate across the most
updated available literature on VI-RADS for NMI vs. MIBC discrimination.
2. Materials and Methods
This systematic review and meta-analysis was conducted according to Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13]. A research question was
established based on the Patient-Index Test-Comparator-Outcome-Study design (PICOS) criteria as the
following: what is overall inter-reader agreement among genitourinary radiologists applying VI-RADS
for NMIBC from MIBC discrimination? Furthermore, our goal was to compare current evidence within
available population-based retrospective and prospective cohort studies. In particular, we determined
the pooled Cohen’s κ and/or Intraclass correlation coefficients (ICCs) among radiologists with different
level of experiences and genitourinary (GU)-specialized volume institutions.
2.1. Evidence Acquisition
We performed a systematic review of the literature in PubMed, Web of Science, Embase,
and Cochrane from inception to 30 July 2020, without language restriction, to identify studies
that examined the implementation of pre-TURBT VI-RADS scoring criteria for BCa staging purposes
and evaluated the extent of agreement between the radiologists involved. The reference lists of the
included studies were also screened for relevant articles. Only original population-based prospective
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and retrospective cohort studies were included and critically evaluated (Level of Evidence: II and III-a).
Case reports, abstracts, and meeting reports were excluded from the analysis. Search terms included but
were not limited to: bladder cancer, AND Vesical Imaging-Reporting and Data System or VI-RADS AND
multiparametric magnetic resonance imaging or mpMRI AND inter-reader agreement or inter-rater
variability AND bladder cancer clinical staging AND radiologists agreement AND preoperative imaging
modalities; secondary fields: non-muscle invasive bladder cancer and magnetic resonance imaging;
muscle-invasive bladder cancer and magnetic resonance imaging; VI-RADS diagnostic accuracy and
inter-reader agreement; bladder cancer stage discrimination; rater characteristics; population-based
prospective cohort studies, population-based retrospective cohort studies. A flow diagram and
comprehensive list of search terms has been summarized in Figure 1 and Table S1, respectively.
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
2.2. Selection of the Studies and Criteria of Inclusion
Entry into the analysis was restricted to data collected from original articles that examined patients
with primary and/or recurrent BCa diagnosis, which assessed final BCa extension through surgical
specimen both from TURBT/Re-TURBT or radical cystectomy (RC), and that aimed to report inter-raters
performance of VI-RADS for NMI vs. MIBC discrimination. Moreover, only those studies including
sufficient data to retrieve inter-reader agreement determination for the outcome of interest (VI-RADS
score) and which assessed both “per-patient” and/or “per-lesion” analysis were considered eligible for
further consideration. Additionally, studies were considered eligible if all readers were board-certified
radiologists with at least 5 years of experience in the Genito-urinary (GU)-MRI imaging, at least two
readers were actively involved in the imaging acquisition and revision, and if VI-RADS imaging
protocol was followed as previously described according to the original document [7].
Articles were excluded if they met one or more of the following criteria: inadequate information
for data extraction or quality assessment; inclusion of study population consisting of <20 patients;
presented outcomes which dealt with other topics (e.g., inter-reader agreement used to assess single
MRI-sequences without VI-RADS, and VI-RADS score for each MRI sequence was provided but an
overall VI-RADS score was not tested for inter-reader variability among radiologists to determine MIBC).
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Three authors (FDG, MP, and BIC) independently screened the titles and abstracts of all articles
using predefined inclusion criteria. The full-text articles were examined independently by the four
(FDG, EDR, CC, and VP) to determine whether or not they met the inclusion criteria. Final inclusion
was determined by consensus of all investigators. Selected articles meeting the inclusion criteria were
then critically analyzed.
The following data were extracted from the included studies by using a standardized form:
origin of study (institution and period of enrollment), size of study population, period of time
prospectively/retrospectively covered, gold standard for MIBC definition, technical parameters of MRI
acquisition (T2WI slice thickness, b values used for DWI, and temporal resolution of DCE MRI), details
regarding MRI interpretation (number and experience of readers, and whether they were blinded or
not), the VI-RADS cutoff value used for determining MIBC on MRI, outcomes related to diagnostic
performance of VI-RADS (sensitivity, specificity, positive and negative predictive value (PPV, NPV)),
and finally patient’s baseline characteristics and BCa pathological features (e.g., mean age and range of
patients, number of tumors, percentage of patients with MIBC, histological subtypes of tumors).
2.3. Assessment of Quality for the Included Studies and Statistical Analysis
To assess the risk of bias (RoB), all included reports were independently reviewed using the
“Quality Appraisal of Diagnostic Reliability (QAREL) Checklist.” Two reviewing authors (FDG and
MP) independently assessed sampling bias and the representativeness of subjects and raters as well as
rater blinding and the order in which raters or subjects were examined. Additionally, the suitability
of the time interval among repeated measurements, whether the test was applied and interpreted
appropriately, and finally the statistical analysis of reliability were considered. Publication bias was
tested both by visual assessment of the Deeks’ funnel plot and calculation of p value using the Deeks’
asymmetry test [14]. The Trim-and-Fill method together with Egger’s regression test were implemented
to explore the possible nature of studies “missed” in the single outcome and the relative importance of
small-study effect [15]. We compared treatments using pooled weighted Cohen’s κ and 95% Confidence
Intervals (CI) considering values as: <0.20 poor reliability, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80
good, and 0.81–1.00 considered excellent [16]. Sensitivity analyses were performed to assess the
contribution of each study to the pooled estimate by excluding individual trials one at a time and
recalculating the pooled estimates for the remaining studies. Evaluation for presence of heterogeneity
was done using [17]: (1) Cochran’s Q-test with p < 0.05 signifying heterogeneity; (2) Higgins I2 test
with inconsistency index (I2) = 0–40%, heterogeneity might not be important; 30–60%, moderate
heterogeneity; 50–90%, substantial heterogeneity; and 75–100%, considerable heterogeneity. The pooled
weighted mean κ estimate was calculated using a random effects model [18]. Our results are graphically
displayed as forest plots (all studies or according to sub-groups analysis), with pooled κ indicating
overall agreement among readers to discriminate from NMIBC to MIBC using VI-RADS criteria.
Meta-regression analyses were performed using available clinical and radiological variables
retrieved among the studies. Pooled weighted κs were plotted against the following available
quantitative variables: range of study time screened (months retrospectively or prospectively imputed),
months from original VI-RADS description, total number of patients screened, and the overall
number of years of experience among the different radiological groups. The point estimates of the
weighted mean κ were obtained and plotted with the area of the circles proportional to the inverse of
the squared standard errors of the studies included. A second set of meta-regression analyses were
conducted implementing categorical variables (sub-groups analysis) such as study design implemented
(prospective vs. retrospective), proportion of MIBC detected (<30 vs. >30%), magnetic strength (1.5 vs.
3 T), T2WI slice thickness (3 vs. 4 mm), and VI-RADS cut-off for MIBC (≥4 vs. ≥3). Calculations were
accomplished using Stata version 16.1 (Stata Corporation, College Station, TX, USA).
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3. Results
3.1. Search Results
The initial search yielded 133 articles (PubMed: 113; Cochrane Library: 4; and Embase: 16).
Forty-eight were excluded as they contained overlapping data or were duplicates appearing in multiple
databases. Of the remaining 85, 75 were further excluded because these did not examine VI-RADS
(54), contained only MRI-based sequence information (7), were review papers, or editorials (14).
Full-text articles were then reevaluated and critically analyzed for the remaining 10 journal references.
Within this in-depth review, a further 2 did not meet the inclusion criteria. The remaining 8 studies
were included in our review (Figure 1). No study was considered to be seriously flawed as per the
“Quality Appraisal of Diagnostic Reliability (QAREL) Checklist.” Studies’ risk to performance bias was
overall moderately low with some attrition bias due to incomplete outcome data across all the studies.
Individual RoB as well as visual assessment of the Deeks’ funnel plots are illustrated in Table S2,
and Figures 2b and 3b.
Figure 2. Pooled inter-reader agreement for the studies included in the quantitative analysis. (a)
Forest plot reporting the pooled inter-reader agreement among the 7 studies analyzed (excluding
Sakamoto et al.); (b) Deeks’ funnel plot (test for small-study effect, p < 0.001); (c) “Trim and Fill” method
suggesting imputed studies missing to remove asymmetry from the funnel plot.
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Figure 3. Sub-group analysis according to study design. (a) Forest plot reporting the pooled inter-reader
agreement according subgroup analysis of the studies (b) Deeks’ funnel plot according to “study
design” subgroup.
3.2. Location, Design, and Characteristics of the Studies Population
Patient/tumors description, main findings, and study characteristics of the whole studies included
are summarized in Table 1. Of the 8 included articles [8,19–25], 3 were conducted in Italy [8,19,24] and
2 in Japan [20,25], while the remaining were from China [21], Egypt, and Korea [22,23], covering an
overall time period between February 2019 and April 2020. Overall, the number of patients included
was 1016, varying from 32 to 340 in single experiences, while the prevalence of MIBC ranged from
n = 6, 10.3% to n = 62, 50%. Three study designs [8,22,24] were prospective reporting outcomes from
primary or recurrent BCa cases. Out of these, the article from Del Giudice et al. [8] was the sole to
analyze a large cohort of patients within prespecified limits of enrolling time (i.e., December 2017–May
2019) and more strict inclusion criteria with regard of previous BCa history and pathology related
exclusion features (i.e., no CIS or non-urothelial carcinomas), while the other two experiences [22,24]
did not report the same information thus suffering from potential higher RoB. The remaining five
studies [19–21,23,25] were retrospective, assessing both urothelial and other histology variants of BCa.
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All studies were performed at single centers using either TURBT or a combination of TUR and partial
or RC as the reference standard. No study solely used cystectomy as the reference standard. In all but
two of the above studies, confirmatory repeat TUR was performed for appropriate clinical settings
(e.g., high-grade NMIBC or insufficient muscle tissue in TUR specimen) to reduce underestimation
of MIBC.
3.3. Technical Imaging Modalities and Readers Characteristics
All the studies included were considered eligible as per VI-RADS protocol criteria originally
described. Table 2 summarizes studies of MRI-specifications and radiological characteristics. MpMRI
had been performed prior to TURBT in all included studies except for one, which consisted of a
mixture of pre- and post-TUR patients [21]. The majority of the studies implemented at a 3T MRI
scanner [8,19,21,23–25] with T2-weighted images including slice thickness of 3 mm [8,19,22,24,25]
or only 4 mm [20,21,23,25] respectively. Diffusion-weighted images were acquired homogeneously
among the studies with high b values of 1000 s/mm2 or higher. Although protocols for DCE MRI
varied among studies, temporal resolution was sufficient for the depiction of early enhancement of
the inner layer followed by tumor enhancement required according to VI-RADS evaluation. Only the
study of Sakamoto et al. [25] compared two different MRI protocols within the same study population.
Their findings were based on the multiparametric vs. biparametric approach with additional evaluation
of apparent diffusion coefficient (ADC) measured on diffusion-weighted magnetic resonance imaging
therefore will be subsequently separated from the rest of the cumulative meta-analysis estimates.
Overall, five studies [8,19,21,22,25] included two readers for the VI-RADS scoring process and for
definitive consensus in the case of discrepancies assuming the most experienced opinion as the definitive
one. In all these cases, a κ estimate with 95%CI or SE was reported. Two studies [23,24] enrolled three
different readers with increasing levels of experience. In the experience of Marchioni et al. [24], a
third and more experienced reader was consulted only in the case of discrepancies among the first
two radiologists, while in the study of Hong et al. [23] all three raters were independently involved
in the diagnostic VI-RADS assignment. As a consequence, both in the study of Hong et al. [23]
and Ueno et al. [20], who involved five different board-certified GU-radiologists, the measure of
inter-variability estimate was the ICCs with 95% CI or SE. In all the examined articles, the readers
were blinded to the pathological findings and reported the outcomes implementing a cutoff VI-RADS
score of ≥3 to determine MIBC or also ≥4 in five studies [19,20,23–25]. The overall cumulative level
of radiologist experience was declared in only five studies ranging from a minimum of 24 years to a
maximum of 47 years.
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Table 1. Clinical and demographic characteristics of the studies enrolled in the systematic review and meta-analysis. SD, Standard Deviation, IQR, Inter Quartile































Retrospective 75 75 69 (62–78) Tis–T3a 22, 29.3% 100 TUR <6 wk III-a





Retrospective 74 74 NA Tis–≥T2 37, 50% 95.9 TUR NA III-a





Retrospective 340 340 64 (27–87) Ta–T4 85, 25% 100 TUR, PC, RC <2 wk III-a
Makboul et al.
[22], 2019, Egypt
NA Prospective 50 50 57.2 T1–T4 18, 36% NA TUR NA II




Prospective 231 231 65.5 (47–79) Ta–T4 62, 27% 100 TUR, RC <6 wk II





Retrospective 32 66 73 (50–90) NA 10, 15.2% NA TUR, RC <2 wk III-a
Marchioni et al.
[24], 2020, Italy






Retrospective 176 176 73 (30–95) Ta–≥T2 46, 26% 100 TUR NA III-a
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Table 2. Radiological and MRI-specific characteristics of the studies enrolled in the systematic review and meta-analysis. T2WI, T2-Weighted Imaging; DWI, Diffusion
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Hong et al. [23],
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Consensus 24 Yes 3 4–5; 3.5 0–1000; 0–2000 NA
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3.4. Interobserver Agreement Estimates Among GU Readers
All of the studies reporting data on inter-reader reliability for VI-RADS to detect MIBC reported
different associations with a range of mean weighted estimates κ from 0.43 to 0.98. As there was
evidence for the presence of substantial heterogeneity between the studies: Q = 185.92 (d.f. = 7),
p < 0.001; I2 = 92.7%, we reported results according to a random-effects model registering pooled K
estimates of 0.83 (95%CI: 0.78–0.88) (Figure S1a). However, since the study of Sakamoto et al. [25]
was flawed by a significantly higher RoB due to substantial differences in the acquisition protocol,
we therefore repeated our analysis with only seven studies [8,19–24], slightly reducing heterogeneity:
Q = 114.97 (d.f. = 6), p < 0.001; I2 = 89.9% and obtaining a cumulative κ estimates of 0.87 (95%CI:
0.83–0.91) (Figure 2a). Exploring heterogeneity among the articles, sub-group analysis set for study
design (retrospective vs. prospective) revealed the presence of the highest heterogeneity among those
with a retrospective design (p < 0.001; I2 = 89.5%) rather than those with a prospective (p < 0.26;
I2 = 0%) (Figure 3 and Table 3).
Table 3. Meta-regression analysis according to subgroup stratification; CI, Confidence Interval.
Subgroup Covariate N. of Studies
Meta Regression (Pooled Agreement)
Inter-Reader 95% CI p Value
Sample size ≤100 5 0.89 0.84 0.93 0.74
>100 2 0.87 0.82 0.93
MIBC
proportion
≤30 5 0.88 0.83 0.93 0.57
>30 2 0.86 0.81 0.91
Study design Retrospective 4 0.91 0.87 0.95 <0.001
Prospective 3 082 0.79 0.86
Number of
readers
2 4 0.85 0.81 0.90 0.01
>2 3 0.93 0.89 0.97
Magnetic
strength
1.5 T used 2 0.86 0.81 0.91 0.57
3.0 T only 5 0.88 0.83 0.93
VI-RADS
cutoff score
≥3 6 0.88 0.84 0.92 0.12
≥4 1 0.76 0.62 0.90
Inspection of the funnel plot suggested that for all the 7 studies together, there was a significant
small-study effect with two studies tending to have a higher outliner estimates as depicted in Figure 2b.
Egger’s regression test showed indeed significant small-study effect (p < 0.001) whilst the “Trim and
Fill” method suggested that three “missing” studies would need to be included to remove asymmetry
from the funnel plot (Figure 2c). With these hypothetical studies included, the pooled inter-reader
agreement having accounted for publication bias was estimated to be 0.92 (95% CI: 0.88–0.96). Funnel
plot inspection grouped for study design graphically displayed the existing asymmetry between
retrospective and prospective analyses (Figure 3b).
A meta-regression summary and plots have been reported in Table 4 and Figure 4. As possibly
expected, we found a negative independently significant trend for the quantitative % of MIBC detected
in each single study and final agreement (Coeff: −0.019, SE = 0.007; p = 0.003), while overall years
of MRI experience among the different groups revealed an increased association in the measure of
ascertainment (Coeff: 0.036, SE = 0.009; p < 0.001).
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Table 4. Meta-regression analysis quantitative variables retrieved among the studies included in the
analysis. SE; Standard Error; CI, Confidence Interval; GU, Genito-Urinary.
Quantitative
Covariates
Simple Meta-Regression Multivariable Meta-Regression
Coef. SE p Value 95% CI Coef. SE p Value 95% CI
Sample Size. n 0.00004 0.00016 0.801 −0.00026 0.00034 - - - - -
Mean age (years) 0.004846 0.00306 0.113 −0.00115 0.01084 - - - - -
% ≥T2 −0.00327 0.00132 0.013 −0.00585 −0.00069 −0.019 0.007 0.003 0.007 0.032
Mo. from VI-RADS
publication
0.00480 0.00312 0.124 −0.00131 0.01090 - - - - -
Range of enrollment −0.00009 0.00047 0.854 −0.00102 0.00084 - - - - -
Total GU-MRI
experience
0.01351 0.00216 0.025 0.00419 0.02282 0.036 0.009 0.001 0.019 0.053
Figure 4. Meta-regression plots of the quantitative variables retrieved among the studies included in
the analysis.
4. Discussion
The adoption of any of the available “Xxx Imaging-Reporting and Data System” for a variety
of malignancies, including breast cancer, liver cancer, lung cancer, and head and neck cancers have
been adopted worldwide and implemented among radiologists to achieve a reproducible common
language to standardize diagnostic interpretation. In urologic oncology, mpMRI of the pelvis has
changed the paradigm in the detection, characterization, and management of prostate cancer, including
allowing for the ability of targeted biopsies, in refining treatment planning and patient selection for
active surveillance, and assessment of post-treatment effects [26,27]. However, the interpretation of
mpMRI remains difficult and with substantial inter-reader variability that had led to the development
of an original (v.1) and then an updated version (v.2 and 2.1) of the Prostate Imaging Reporting and
Data System (PI-RADS) [27–29]. All these efforts have led the European Association of Urology (EAU)
Guidelines to strongly recommend adherence to PI-RADS guidelines for mpMRI acquisition and
interpretation [30]. While we acknowledge the existence of two very separate diagnostic objectives
between PI-RADS and VI-RADS, nevertheless, these criteria certainty share the common aim of
pursuing a higher reliability among readers for the diagnostic outcomes if compared to a merely
subjective interpretation of the MRI sequences.
Similarly, preoperative diagnostic tools such as computer tomography (CT) and MRI are available
for clinical stage determination of BCa, but still lack a high degree of reliability. The accuracy of
MRI for primary BCa staging varies indeed from 73% to 96%, according to various studies [1,4,31].
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With the aim of standardizing staging, diagnosis, and eventually, therapeutic response to neoadjuvant
systemic regimens, the VI-RADS scoring system has been recently introduced and validated through a
consensus-driven approach to reproducible imaging and reporting [7].
Although it is relatively novel, a growing body of evidence from both retrospective and prospective
studies is becoming available, systematically testing VI-RADS for diagnostic applications both for
preoperative risk stratification and assessment of therapeutic response post chemotherapy [8,11,12].
Two recent meta-analyses describe the ability of VI-RADS to differentiate between superficial and
muscle-invasive disease in a preoperative setting [9,10]. As expected, even if AUC values were similarly
high when setting both threshold of ≥3 or a ≥4 for MIBC, the sensitivity and the positive likelihood
ratio were found higher for this last one thus delineating two separate plausible profiles to interpret
VI-RADS related on one hand to muscle status prediction or on the other, to preoperative assessment
before TURBT and eventually RC.
However, none of the above studies has quantitatively assessed the diagnostic reliability among
readers of VI-RADS to predict MIBC. Ours is the first meta-analysis of the currently available evidence.
Encouragingly, we found that the pooled inter-agreement estimates ranged from good to excellent in
accordance with the different studies enrolled. We readily admit the existence of some heterogeneity
among the outcomes reported. However, we would partly attribute this to different study designs
among the eligible studies (retrospective vs. prospective). At subgroup analysis, the retrospective
studies were indeed found to be influenced by an over-estimating effect upon inter-reader agreement
due to the existence of some potential bias. On the other hand, some of the heterogeneity could
be also attributed to the intrinsic limitations of the Cohen’s Kappa meta-analysis. Although all the
studies relied on the original VI-RADS publication for scoring [7] and were therefore significantly
comparable in terms of cohort characteristics, positivity threshold (score ≥3), and reported similar
MIBC prevalence, each single Kappa value might not be considered as equivalent to a population
parameter, thus the derived variance weighted mean estimated would be possibly influenced by the
marginal distributions. Standardizing the interpretation and reporting approach along with continued
good predictive performance of the VI-RADS system is the basis of the overall quality of the current
meta-analysis and furthermore will represent the additional opportunities for improving upon the
currently suboptimal TUR staging algorithm which can understage a significant number of cases,
especially when the muscularis propria has not been sampled [32,33].
Currently, the reproducibility of VI-RADS versus bladder MRI without VI-RADS has become
a debated issue in the radiologist’s and urologist’s community. To date, there are no data showing
differences in inter-readers’ agreement comparing MRI using VI-RADS and MRI alone. However,
the controversy is wrongly based on the assumption of comparing VI-RADS vs. MRI. VI-RADS is
a scoring system developed to standardize MRI interpretation and reporting that has proved to be
reliable as score supporting the role of MRI in the diagnosis of MIBC. As such, it is unlikely that
VI-RADS and MRI alone show very different performance; however, MRI does not allow to stratify
patient prognostic risk according to muscle invasiveness likelihood. In fact, VI-RADS has practical
implication in the management of treatment of naïve patients undergoing MRI before TURBT for
staging purposes, that MRI alone would not have. Authors have suggested the role of VI-RADS as
scoring that might tailor therapeutic planning according to patients’ risk as per precision personalized
medicine, lowering under- and over-treatment and overall costs [5,8].
MpMRI of the bladder with VI-RADS scores might become as a tool for initial hematuria work-out,
prediction of tumor extent, response to systemic therapy, as well as a clinical predictor for perioperative
outcomes. This could lead to the developments of diagnostic pathways to early identify prognostic
features and novel nomograms among selected patient’s categories. Accordingly, the Bladder Path
trial (Available online: https://www.birmingham.ac.uk/research/crctu/trials/bladder-path/index.aspx,
October 2020), where TURBT has been investigated for being substituted by mpMRI after bladder
biopsy demonstrated the presence of BCa, is moving forward to prove the safety possibility for a more
rapid and immediate radical intervention in patients with muscle-invasive disease according to mpMRI
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findings. Moreover, our group has recently identified VI-RADS score 5 with the highest accuracy to
predict locally advanced BCa at RC (≥pT3) as well as identified score 5 as an independent unfavorable
predictor for relevant delayed time to cystectomy (i.e., >3 months from TURBT diagnosis of MIBC;
odds ratio [OR] 2.81, 95% CI: 1.20–6.62) [34]. All of these future clinical perspectives may lead VI-RADS
to become a user-friendly tool for preoperative loco-regional staging as well as a reliable predictor
aiding to drive the urological decision-making process for specifically selected BCa categories.
Although all such promising clinical implications, van der Heijden and Witjes have reasonably
and rightly addressed the lack of data regarding reproducibility of the scoring system among different
centers warranting the need of multicenter studies [35].
Our results suggest that VI-RADS offer a standard methodology for radiologists in the acquisition,
interpretation, and reporting of MRI, nonetheless several limitations warrant mentioning. First,
the number of included studies was relatively small (n = 8) and there was some heterogeneity among
the included studies. Nevertheless, the overall number of patients included was greater than 1000,
which mitigates any potential statistical power issues. We also found that greater experience with
VI-RADS was the most significant predictor of inter-rater reliability, which could create differential
results amongst those tertiary centers most familiar with the system. A higher percent of MIBC
prevalence among the studies also corresponded to lower agreement, which is plausible considering
the direct clinical and psychological implication to address to a patient when such a diagnosis is
presumed. Finally, we admit that possible confounding from other factors, such as time from VI-RADS
development or technical aspects (i.e., magnet strength), could occur which will require further
exploration in future analyses.
5. Conclusions
VI-RADS is a promising diagnostic tool characterized by excellent inter-observer variability in
pre-TURBT identification of patients with MIBC. Although this meta-analysis represents the first initial
proof of significant agreement of VI-RADS for BCa staging among radiologists working into GU-MRI
dedicated imaging institutions and with a significant overall high level of expertise, additional larger,
multicenter experiences will be necessary to confirm this initial promising trend. In particular, technical
aspects such as the role of magnetic field strength or slice thickness as well as the influence of tertiary
compared to non-tertiary medical centers will need to be further explored to confirm whereas mpMRI
and VI-RADS can safely be addressed in routine clinical practice to evaluate the presence of muscle
invasiveness before a staging/therapeutic TUR procedure.
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